The sensitivity of our mobile-phone-based targeted sequencing method for extracted tumour DNA is currently limited by the sequencing depth and accuracy to ∼5% mutant:wild-type ratio, which is similar to diagnostic KRAS PCR Kits (the therascreen KRAS RGQ PCR Kit, https://www.qiagen.com/us/resources/technologies/oncology-companion-diagnostics/therascreen-kras-test-usa-labs/#performance). This evidence concerns the gene KRAS and neoplasm.